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Supplemental data legends 	
 	
Supplemental data (Figure S1). Illustration showing the influence of HBV on host gene 	
expression.  	
In the course of HCC development gene expression in hepatocyte nuclei can be influenced through HBV 	
on both the genome and the epigenome levels. Influence on the genome level involves integration of 	
HBV DNA into the host genome. Further, HBx is thought to modulate the expression of host genes via 	
regulation of CpG signaling and histone modification patterns. To date, the interactions of the cccDNA 	
and HBx with the 3D host higher order nuclear architecture remain unexplored.  	
 	
Supplemental data (Figure S2). Illustration of selected methods. 	
A. cccDNA amplicons from several cell lines were separated on agarose gels to monitor the replication of 	
HBV. These amplicons were further used for Sanger sequencing to verify the HBV-D3 genotype.  	
B. Alignment of an HBV genomic region-of-interest containing a conserved SpeI restriction site flanked 	
by 2 HaeIII restriction sites. PCR strategy to amplify host genomic DNA from cccDNA-host genome 	
hybrids is depicted below. C. Principle and work flow of the 4C method. 	
 	
 	
Supplemental data (Figure S3). Fluorescence microscopy of NLS- or NES-HBx-RFP-transfected 	
hepatocytes in vitro. Verification of RFP-fusion protein expression in transfected cells demonstrating 	
nuclear (A) or extranuclear (B) localization. 	
 	
Supplemental data (Figure S4). qPCR-derived gene expression patterns of murine hepatocytes 	
transfected with several different HBx constructs and comparative analyses of the consequences 	
of directed HBx-domain depletion. 	
MMH-D3 hepatocytes were transfected with different NLS-HBx-RFP plasmid constructs (wild type HBx 
and four different partial deletion constructs: ΔA-ΔD; compare to Figure 2A). Relative enrichment of 
mRNAs relevant for the development of HCC are outlined subjected to unsupervised hierarchical cluster 
analysis assembly according to differences in gene expression patterns. 
 
Supplemental data (Figure S5). Correlative analyses of HBV cccDNA-HepaRG genome 
association and actively transcribed genes. 
The gene-poor human chromosome 18 and gene-rich chromosome 19 are shown as further examples to 
complement Figure 3. 
 
 	
Supplemental data (Figure S6). Comparing DNA methylation between circulating HBV DNA 	
and cccDNA from patients’ liver cells. 	
A. The HBV genome map illustrates the position of 3 major CpG islands (CGIs, red boxes covering the 	
GC content graphs – grey boxes illustrate the position of putative CGIs not conserved in all HBV 	
genotypes [1]) and HpaII/MspI restriction sites with respect to important RC DNA features. Two 	
amplicons covering HpaII/MspI restriction sites within CGI1 or CGI2, respectively, were used for qPCR 	
analyses. Primers were: HBV_CGI1fw: 5'-ccgatccatactgcggaactcct-3' with HBV_CGI1rv: 5'-	
agaggtgaagcgaagtgcacac-3' or HBV_CGI3fw: 5'-agctgtgccttgggtggcttt-3' with HBV_CGI3rv: 5'-	
ctgcgaggcgagggagttc-3', repectively. DNA methylation was determined using a combination of DNA-	
methylation sensitive restriction endonuclease digest (HpaII/MspI) and qPCR. 2 amplicons were analyzed 	
and compared. We prioritized this approach over bisulfite-based approaches due to the limited amount of 	
HBV DNA in many small specimens. Another reason was that the selected approach favors the analysis 	
of cccDNA over RC DNA due to the substrate-specificity of restriction endonucleases on double 	
stranded DNA (at least one HpaII/MspI-site of interest in CGI1 corresponds to the ssDNA region of RC 	
DNA). We found that the combinatorial use of DNA methylation-sensitive endonuclease digest and 	
qPCR allowed us a robust detection of HBV DNA retention after HpaII digest, when in parallel 	
compared with MspI digest on even very low amounts of HBV DNA isolated from patient’s sera or liver 	
biopsies. B. It turned out that after HpaII digests the amount of detected HBV DNA from blood 	
(median: 81.30% [25%ile: 66.36%/75%ile: 90.03%] for n=263 with respect to HBV DNA from the same 	
samples digested with MspI) was significantly (p<0.0078) higher than for HBV DNA from infected 	
human liver (median: 38.59% [25%ile: 29.54%/75%ile: 71.12%] for n=11 with respect to HBV DNA 	
from the same samples digested with MspI). These data suggest that the cccDNA in infected human liver 	
cells occurs in a hypomethylated state, if compared with circulating HBV DNA. 	
 	
 	
Supplemental data (Table S1). Gene list qPCR panel PAMM-133R ‘liver cancer’ (Qiagen, Hilden, 	
Germany) 	
Position Unigene Refseq Symbol Description 
A01 Mm.27681 NM_009615 Adam17 A disintegrin and metallopeptidase domain 17 
A02 Mm.6645 NM_009652 Akt1 Thymoma viral proto-oncogene 1 
A03 Mm.439874 NM_007426 Angpt2 Angiopoietin 2 
A04 Mm.19904 NM_007527 Bax Bcl2-associated X protein 
A05 Mm.257460 NM_009741 Bcl2 B-cell leukemia/lymphoma 2 
A06 Mm.238213 NM_009743 Bcl2l1 Bcl2-like 1 
A07 Mm.235081 NM_007544 Bid BH3 interacting domain death agonist 
A08 Mm.335659 NM_007465 Birc2 Baculoviral IAP repeat-containing 2 
A09 Mm.8552 NM_009689 Birc5 Baculoviral IAP repeat-containing 5 
A10 Mm.336851 NM_009812 Casp8 Caspase 8 
A11 Mm.284248 NM_013653 Ccl5 Chemokine (C-C motif) ligand 5 
A12 Mm.273049 NM_007631 Ccnd1 Cyclin D1 
B01 Mm.333406 NM_009829 Ccnd2 Cyclin D2 
B02 Mm.35605 NM_009864 Cdh1 Cadherin 1 
B03 Mm.334841 NM_019707 Cdh13 Cadherin 13 
B04 Mm.195663 NM_007669 Cdkn1a Cyclin-dependent kinase inhibitor 1A (P21) 
B05 Mm.2958 NM_009875 Cdkn1b Cyclin-dependent kinase inhibitor 1B 
B06 Mm.4733 NM_009877 Cdkn2a Cyclin-dependent kinase inhibitor 2A 
B07 Mm.336848 NM_009805 Cflar CASP8 and FADD-like apoptosis regulator 
B08 Mm.291928 NM_007614 Ctnnb1 Catenin (cadherin associated protein), beta 1 
B09 Mm.1401 NM_009911 Cxcr4 Chemokine (C-X-C motif) receptor 4 
B10 Mm.29629 NM_001001602 Dab2ip Disabled homolog 2 (Drosophila) interacting protein 
B11 Mm.210875 NM_015802 Dlc1 Deleted in liver cancer 1 
B12 Mm.18036 NM_007891 E2f1 E2F transcription factor 1 
C01 Mm.252481 NM_010113 Egf Epidermal growth factor 
C02 Mm.8534 NM_007912 Egfr Epidermal growth factor receptor 
C03 Mm.258397 NM_177821 Ep300 E1A binding protein p300 
C04 Mm.5126 NM_010175 Fadd Fas (TNFRSF6)-associated via death domain 
C05 Mm.1626 NM_007987 Fas Fas (TNF receptor superfamily member 6) 
C06 Mm.397619 NM_010210 Fhit Fragile histidine triad gene 
C07 Mm.389712 NM_010228 Flt1 FMS-like tyrosine kinase 1 
C08 Mm.297906 NM_008057 Fzd7 Frizzled homolog 7 (Drosophila) 
C09 Mm.1360 NM_008655 Gadd45b Growth arrest and DNA-damage-inducible 45 beta 
C10 Mm.299292 NM_013541 Gstp1 Glutathione S-transferase, pi 1 
C11 Mm.267078 NM_010427 Hgf Hepatocyte growth factor 
C12 Mm.254493 NM_020259 Hhip Hedgehog-interacting protein 
D01 Mm.334313 NM_008284 Hras1 Harvey rat sarcoma virus oncogene 1 
D02 Mm.3862 NM_010514 Igf2 Insulin-like growth factor 2 
D03 Mm.21300 NM_008341 Igfbp1 Insulin-like growth factor binding protein 1 
D04 Mm.29254 NM_008343 Igfbp3 Insulin-like growth factor binding protein 3 
D05 Mm.4952 NM_010570 Irs1 Insulin receptor substrate 1 
D06 Mm.263396 NM_010578 Itgb1 Integrin beta 1 (fibronectin receptor beta) 
D07 Mm.285 NM_010612 Kdr Kinase insert domain protein receptor 
D08 Mm.255219 NM_010703 Lef1 Lymphoid enhancer binding factor 1 
D09 Mm.1639 NM_008562 Mcl1 Myeloid cell leukemia sequence 1 
D10 Mm.86844 NM_008591 Met Met proto-oncogene 
D11 Mm.4619 NM_008628 Msh2 MutS homolog 2 (E. coli) 
D12 Mm.343101 NM_010829 Msh3 MutS homolog 3 (E. coli) 
E01 Mm.130883 NM_026002 Mtdh Metadherin 
E02 Mm.2444 NM_010849 Myc Myelocytomatosis oncogene 
E03 Mm.256765 NM_008689 Nfkb1 Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1, p105 
E04 Mm.400954 NM_010937 Nras Neuroblastoma ras oncogene 
E05 Mm.379474 NM_177906 Opcml Opioid binding protein/cell adhesion molecule-like 
E06 Mm.221403 NM_011058 Pdgfra Platelet derived growth factor receptor, alpha polypeptide 
E07 Mm.7906 NM_023371 Pin1 Protein (peptidyl-prolyl cis/trans isomerase) NIMA-interacting 1 
E08 Mm.245395 NM_008960 Pten Phosphatase and tensin homolog 
E09 Mm.292547 NM_011198 Ptgs2 Prostaglandin-endoperoxide synthase 2 
E10 Mm.254494 NM_007982 Ptk2 PTK2 protein tyrosine kinase 2 
E11 Mm.24163 NM_023258 Pycard PYD and CARD domain containing 
E12 Mm.292510 NM_009007 Rac1 RAS-related C3 botulinum substrate 1 
F01 Mm.12091 NM_019713 Rassf1 Ras association (RalGDS/AF-6) domain family member 1 
F02 Mm.273862 NM_009029 Rb1 Retinoblastoma 1 
F03 Mm.425236 NM_011261 Reln Reelin 
F04 Mm.757 NM_016802 Rhoa Ras homolog gene family, member A 
F05 Mm.378894 NM_019732 Runx3 Runt related transcription factor 3 
F06 Mm.19155 NM_009144 Sfrp2 Secreted frizzled-related protein 2 
F07 Mm.100399 NM_008540 Smad4 MAD homolog 4 (Drosophila) 
F08 Mm.34407 NM_001042660 Smad7 MAD homolog 7 (Drosophila) 
F09 Mm.130 NM_009896 Socs1 Suppressor of cytokine signaling 1 
F10 Mm.3468 NM_007707 Socs3 Suppressor of cytokine signaling 3 
F11 Mm.249934 NM_011486 Stat3 Signal transducer and activator of transcription 3 
F12 Mm.4269 NM_013685 Tcf4 Transcription factor 4 
G01 Mm.10109 NM_009354 Tert Telomerase reverse transcriptase 
G02 Mm.137222 NM_031199 Tgfa Transforming growth factor alpha 
G03 Mm.248380 NM_011577 Tgfb1 Transforming growth factor, beta 1 
G04 Mm.172346 NM_009371 Tgfbr2 Transforming growth factor, beta receptor II 
G05 Mm.38049 NM_021297 Tlr4 Toll-like receptor 4 
G06 Mm.193430 NM_020275 Tnfrsf10b Tumor necrosis factor receptor superfamily, member 10b 
G07 Mm.1062 NM_009425 Tnfsf10 Tumor necrosis factor (ligand) superfamily, member 10 
G08 Mm.222 NM_011640 Trp53 Transformation related protein 53 
G09 Mm.282184 NM_009505 Vegfa Vascular endothelial growth factor A 
G10 Mm.389339 NM_144783 Wt1 Wilms tumor 1 homolog 
G11 Mm.259879 NM_009688 Xiap X-linked inhibitor of apoptosis 
G12 Mm.221992 NM_009534 Yap1 Yes-associated protein 1 
H01 Mm.3317 NM_010368 Gusb Glucuronidase, beta 
H02 Mm.299381 NM_013556 Hprt Hypoxanthine guanine phosphoribosyl transferase 
H03 Mm.2180 NM_008302 Hsp90ab1 Heat shock protein 90 alpha (cytosolic), class B member 1 
H04 Mm.343110 NM_008084 Gapdh Glyceraldehyde-3-phosphate dehydrogenase 
H05 Mm.328431 NM_007393 Actb Actin, beta 
 	
Supplemental data (Table S2). Host cellular gene expression in three different cell lines. 	
RNA-seq derived host cell gene expression including a color legend is provided in a separate file. HepaRG 	
cells were analyzed immediately before HBV infection (t=0) and subsequently at three different time 	
points (t = 1-3). Moreover, the HBV-positive hepatoma cell lines HepG2.2.15 and HepG2H1.3 were 	
analysed. For data sorting 2 main criteria were applied: 1. lines 13-125 represent 113 out of 157 listed liver 	
marker genes (with reference to the Human Protein Atlas [https://www.proteinatlas.org]). It is notable 	
that - in contrast to HepaRG cell - many of these liver markers exhibit decreased levels in HepG2.2.15 	
and HepG2H1.3 cells or, respectively, are not detectable. Table S2 is provided as a separate 	
Supplementary Material file (Excel spreadsheet). 	
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